<DOC>
	<DOCNO>NCT01573624</DOCNO>
	<brief_summary>Brief Summary : The purpose study characterize dose response GSK573719 combination Fluticasone furoate 100mcg patient asthma . Treatment inhale Fluticasone furoate Fluticasone furoate/Vilanterol include active control . Detailed Description : Long act muscarinic receptor antagonist ( anti-cholinergic bronhcodilator ) exert effect via distinct complementary bronchodilator mechanism large small airway . Most experience old anti-cholinergics acute use little known effect chronic use asthma . This multicenter , randomize , double-blind , crossover study evaluate 5 dos inhale GSK573719 inhale 14 day patient asthma . Fluticasone furoate ( 100 mcg ) Fluticasone furoate/Vilanterol ( 100/59mcg ) include active comparator . Each eligible subject receive sequence 3 7 potential treatment total 3 treatment period per subject . The total duration subject participation approximately 14 week .</brief_summary>
	<brief_title>Evaluate Safety , Efficacy Dose Response GSK573719 Combination With Fluticasone Furoate Subjects With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Outpatient 18 year age old Visit 1 Diagnosis Asthma Male eligible Female Prebronchodilator FEV1 4080 % predict normal value Visit 1 Demonstrated reversibility ≥12 % ≥200mL FEV1 within 40 minute follow albuterol Visit 1 A need regular controller therapy ( i.e. , inhaled corticosteroid alone combination long‐acting beta‐agonist , leukotriene modifier etc. , ) minimum 8 week prior Visit 1 . History Life threaten asthma Respiratory infection resolve Asthma exacerbation Concurrent respiratory disease Current Smokers Other disease uncontrolled disease disease state , opinion investigator , would put safety patient risk study participation would confound interpretation efficacy result condition/disease exacerbate study A positive Hepatitis B surface antigen positive Hepatitis C antibody and/or HIV Visual clinical evidence oropharyngeal candidiasis Drug milk protein allergy Concomitant medication affect course asthma Use investigational medication within 30 day 5 drug halflives ( whichever longer ) Previous use GSK573719 Any disease preventing use anticholinergic Any condition impairs compliance study protocol include visit schedule completion daily diaries Any subject history alcohol substance abuse Any affiliation Investigator 's site</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Vilanterol ( VI ) ,</keyword>
	<keyword>, Fluticasone Furoate ( FF ) ,</keyword>
	<keyword>Adults</keyword>
	<keyword>Asthma</keyword>
	<keyword>GSK573719 ,</keyword>
</DOC>